Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued paten ...
StockStory.org on MSN
Winners and losers of Q4: Insulet (NASDAQ:PODD) vs the rest of the patient monitoring stocks
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including Insulet ...
Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 ...
Around 1.2 million Australians live with type 2 diabetes, yet there is no government subsidy for CGMs, despite this being well-established ...
Glucotrack (Nasdaq:GCTK) today provided an update on the planned regulatory timeline for its continuous blood glucose monitor ...
Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...
Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 ...
Since its launch in 2025, more than one million users have adopted the Ottai CGM.
A trial testing new treatments aimed at restoring warning signs of low blood glucose in people with type 1 diabetes when ...
Chronic disease management stands at an inflection point. Globally, the number of people living with diabetes continues to climb, and healthcare systems in both developed and emerging markets are ...
Should A1c remain the gold standard for routine monitoring of glucose control in people with diabetes, or is it time to shift ...
The U.S. Food & Drug Administration announced that a glucose meter (a.k.a. a blood sugar meter) company is issuing an important correction for its blood glucose monitoring system. True Metrix is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results